Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells

Cancer Gene Therapy

Volumn 17, Issue 9, 2010, Pages 655-663

  Grandi, P ^a   Fernandez, J ^a   Szentirmai, O ^b   Carter, R ^a   Gianni, D ^a   Sena Esteves, M ^a   Breakefield, X O ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

EGFR; glioma; glycoprotein C; HSV; HSV vector retargeting; mouse tumor model; oncolytic; tropism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; FIREFLY LUCIFERASE; HEPARAN SULFATE; HERPES SIMPLEX VIRUS VECTOR; MUTANT PROTEIN; ONCOLYTIC VIRUS; PROTEIN C; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CELL KILLING; CELL SURFACE; DRUG TARGETING; FEMALE; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL; VIRION; VIROGENESIS; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS INFECTIVITY; WILD TYPE;

ANIMALS; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; FEMALE; GENETIC VECTORS; GLIOMA; HELPER VIRUSES; HEPARITIN SULFATE; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 77955925502     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.22     Document Type: Article

References (51)

1. Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006; 13: 66-71.
2. Fulci G, Chiocca EA. The status of gene therapy for brain tumors. Expert Opin Biol Ther 2007; 7: 197-203.
3. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
4. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815-14820.
5. Smith KE, Janelixde S, Visse E, Badn W, Salford L, Siesjo P et al. Synergism between GM-CSF and IFN gamma: enhanced immunotherapy in mice with glioma. Int J Cancer 2007; 120: 75-80.
6. Grandi P, Bein K, Hadjipanayis C, Wolfe D, Breakefield XO, Glorioso J. Application of HSV-1 vectors to the treatment of cancer. In: Harrington K, Pandha H, Vile R (eds). Viral Therapy of Cancer. John Wiley & Sons, London, 2008.
7. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525-526.
8. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
9. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 2003; 10: 292-303.
10. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J et al. The potential for efficacy of the modified (ICP 34.5(\)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy 2002; 9: 398-406.
11. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.
12. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
13. Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003; 21: 278-292.
14. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007; 7: 181-189.
15. Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, Korokhov N et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother 2006; 55: 1412-1419.
16. Wickham TJ. Targeting adenovirus. Gene Therapy 2000; 7: 110-114.
17. Hacker UT, Wingenfeld L, Kofler DM, Schuhmann NK, Lutz S, Herold T et al. Adeno-associated virus serotypes 1-5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gen Med 2005; 7: 1429-1438.
18. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 2003; 281: 137-178.
19. Frampton ARJ, Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy 2005; 12: 891-901.
20. Laquerre S, Argnani R, Anderson DB, Zucchini S, Manservigi R, Glorioso JC. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998; 72: 6119-6130.
21. Argnani R, Boccafogli L, Marconi PC, Manservigi R. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Therapy 2004; 11: 1087-1098.
22. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 2002; 99: 15124-15129.
23. Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT et al. HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther 2004; 9: 419-427.
24. Laquerre S, Anderson DB, Stolz DB, Glorioso JC. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998; 72: 9683-9697.
25. Nakano K, Asano R, Tsumoto K, Kwon H, Goins WF, Kumagai I et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 2005; 11: 617-626.
26. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-3148.
27. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002; 62: 3335-3339.
28. Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 2000; 88: 962-969.
29. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992; 186: 74-86.
30. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-7731.
31. Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xeno-grafts after labeling using N-succinimidyl 5-iodo-3-pyridine-carboxylate. Cancer Res 1997; 57: 1510-1515.
32. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
33. Herold BC, Visalli RJ, Susmarski N, Brandt CR, Spear PG. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycopro-tein B. J Gene Virol 1994; 75: 1211-1222.
34. Matis J, Lesso J, Mucha V, Matisova E. Purification and separation of enveloped and unenveloped herpes simplex virus particles. Acta Virol 1975; 19: 273-280.
35. Turner DL, Snyder EY, Cepko CL. Lineage-independent determination of cell type in the embryonic mouse retina. Neuron 1990; 4: 833-845.
36. Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L et al. HSV-1 amplicon peptide display vector. J Virol Methods 2003; 107: 71-79.
37. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. In: Machida CA (ed). Viral Vectors for Gene Therapy, Methods and Protocols. Humana Press: Totowa, NJ, 2003. pp 51-60.
38. Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO et al. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res 2004; 64: 273-278.
39. Eisenberg RJ, Ponce de Leon M, Friedman HM, Fries LF, Frank MM, Hastings JC et al. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathol 1987; 3: 423-435.
40. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22: 6865-6872.
41. Tal-Singer R, Peng C, Ponce De Leon M, Abrams WR, Banfield BW, Tufaro F et al. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 1995; 69: 4471-4483.
42. Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods 2004; 33: 179-186.
43. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol Ther 2007; 15: 677-686.
44. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006; 12: 7261-7270.
45. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 2002; 76: 12149-12161.
46. Yamamoto S, Deckter LA, Kasai K, Chiocca EA, Saeki Y. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Therapy 2006; 13: 1731-1736.
47. Pike L, Petravicz J, Wang S. Bioluminescence imaging after HSV amplicon vector delivery into brain. J Gene Med 2006; 8: 804-813.
48. Shah K, Breakefield X. HSV amplicon vectors for cancer therapy. Curr Gene Ther 2006; 6: 361-370.
49. Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J Gene Med 1999; 1: 176-185.
50. Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001; 4: 250-256.
51. Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T et al. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 2001; 7: 561-568.